Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
11:51am, Thursday, 04'th Sep 2025
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
09:21am, Thursday, 04'th Sep 2025
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
09:07am, Thursday, 04'th Sep 2025
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.
Sanofi Shares Sink as Experimental Drug Results Disappoint
04:43am, Thursday, 04'th Sep 2025
Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.
Sanofi shares sink over 9% on weak trial results for experimental inflammation drug
04:01am, Thursday, 04'th Sep 2025
Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
01:46am, Thursday, 04'th Sep 2025
Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Thermo Fisher Scientific Completes Acquisition of Sanofi's Ridgefield, New Jersey Site
08:15am, Tuesday, 02'nd Sep 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi's state-of-the-art sterile f
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
01:31pm, Monday, 01'st Sep 2025
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Now Is The Time To Buy This High-Yielding Trio
01:24pm, Saturday, 30'th Aug 2025
The focus of today will be on CMCSA, AES, and SNY. The trifecta provides a reasonably secure 4.5% average yield, an A- average S&P credit rating, and is 33% undervalued. Comcast Corporation could be s
US FDA approves Sanofi's drug for a rare blood disorder
05:56pm, Friday, 29'th Aug 2025
The U.S. Food and Drug Administration has approved Sanofi's drug to treat a type of blood disorder, the company said on Friday, in a sign that the French drugmaker's $3.7 billion bet on the treatment
Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
05:50pm, Friday, 29'th Aug 2025
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
10:51am, Friday, 15'th Aug 2025
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
01:00am, Thursday, 14'th Aug 2025
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at
